

Kyowa Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2024

(January 1, 2024 - December 31, 2024)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on February 6, 2025 for Fiscal 2024, from January 1, 2024 to December 31, 2024.
- This document is an English translation of the Japanese-language original.
- The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
- Figures presented in these materials have been rounded to the nearest tenth
- Figures inside parenthesis presented in these materials indicate negative values.
- Change amount in these materials presents change amount compared to the previous fiscal year.

Index	Page
I. Consolidated Financial Results	
1. Trends in consolidated profit	1
2. Revenue by regional control function	2
3. Revenue by location of customer	2
4. Capital expenditures and intangible assets investment, depreciation and amortization	2
5. Number of employees by regional control function	2
II. Consolidated Statement of Cash Flows	2
III. Revenue from Main Products	3
IV. R&D Pipeline	6

The average exchange rates for each period were as follows:

Unit: Yen

	FY 2023 results				FY 2024 results				FY 2025 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
USD	132	134	137	140	147	151	151	151	145
GBP	161	164	170	174	187	191	193	193	190
EUR	141	144	148	151	160	163	164	164	160

<p>Contact Kyowa Kirin Co., Ltd. Corporate Communications Department Tel +81 3 5205 7206</p>

I. Consolidated Financial Results
1. Trends in consolidated profit

<Accumulative>

The "*" symbol indicates financial KPIs (numerical guidance) that were set as targets in the FY2021-2025 Medium Term Business Plan.

Unit: Billions of yen

	FY 2023 results				FY 2024 results								FY 2025 forecasts		FY2021-2025 Medium Term Business Plan Financial KPIs
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Rate of change	Jan - Dec latest forecasts	% of forecasts	Jan - Dec	Rate of change	
Revenue	93.5	199.2	306.1	442.2	105.6	233.0	362.8	495.6	53.3	12%	492.0	101%	478.0	(4)%	10% or higher
★ CAGR (compared to FY 2020)	-	-	-	11.6%	-	-	-	11.7%	-	-	11.5%	-	8.5%	-	
Cost of sales	(18.9)	(47.0)	(77.0)	(111.2)	(25.6)	(59.5)	(94.0)	(132.6)	(21.4)	19%	(128.0)	104%	(126.0)	(5)%	
Gross profit	74.6	152.2	229.1	331.0	80.0	173.5	268.8	362.9	31.9	10%	364.0	100%	352.0	(3)%	
Gross profit to revenue ratio	79.7%	76.4%	74.8%	74.9%	75.8%	74.5%	74.1%	73.2%	-	-	74.0%	-	73.6%	-	
Selling, general and administrative expenses	(41.8)	(82.4)	(119.3)	(163.1)	(40.2)	(83.2)	(123.6)	(167.5)	(4.5)	3%	(168.0)	100%	(166.0)	(1)%	
Research and development expenses	(16.6)	(33.7)	(51.2)	(72.1)	(23.3)	(49.2)	(74.3)	(103.5)	(31.4)	44%	(105.0)	99%	(107.0)	3%	Target of 18-20%
★ R&D expense ratio	17.8%	16.9%	16.7%	16.3%	22.1%	21.1%	20.5%	20.9%	-	-	21.3%	-	22.4%	-	
Share of profit (loss) of investments accounted for using equity method	0.8	1.4	2.3	0.9	0.9	3.1	3.5	3.5	2.6	275%	1.0	354%	1.0	(72)%	
Core operating profit	17.0	37.5	60.9	96.8	17.4	44.1	74.4	95.4	(1.4)	(1)%	92.0	104%	80.0	(16)%	25% or higher
★ Core operating profit ratio	18.2%	18.8%	19.9%	21.9%	16.5%	18.9%	20.5%	19.3%	-	-	18.7%	-	16.7%	-	
Other income	0.2	0.5	16.6	16.8	2.6	4.4	13.3	13.1	(3.7)	(22)%					
Other expenses	(2.6)	(14.2)	(16.6)	(21.0)	(2.8)	(4.7)	(16.9)	(19.3)	1.7	(8)%					
Finance income (costs)	1.0	2.2	3.5	4.7	0.8	2.6	0.8	(5.8)	(10.5)	(223)%					
Profit before tax	15.6	26.0	64.3	97.2	18.1	46.5	71.6	83.5	(13.8)	(14)%	92.0	91%	74.0	(11)%	
Income tax expense	(2.8)	(4.4)	(10.8)	(16.1)	(3.5)	(8.7)	(15.7)	(23.6)	(7.5)	47%	(24.0)	98%	(17.0)	(28)%	
Ratio of income tax burden	18.1%	16.9%	16.8%	16.5%	19.2%	18.8%	21.9%	28.3%	-	-	26.1%	-	23.0%	-	
Profit	12.8	21.6	53.6	81.2	14.6	37.8	55.9	59.9	(21.3)	(26)%	68.0	88%	57.0	(5)%	
Profit to revenue ratio	13.6%	10.9%	17.5%	18.4%	13.9%	16.2%	15.4%	12.1%	-	-	13.8%	-	11.9%	-	

EPS (¥/share)	23.74	40.27	99.62	151.03	27.26	70.76	105.20	113.06	(37.97)	-	128.42	108.91	-	
Core EPS (¥/share) ¹	27.33	61.40	99.69	157.58	27.46	71.16	110.52	121.44	(36.14)	-	131.26	119.23	-	
Annual dividend (¥/share)				56.00				58.00	2.00		58.00	60.00	-	
★ Dividend payout ratio (%) ²				35.54				47.76	12.22		44.19	50.32	-	Target of 40%
★ ROE (%)				10.15				7.10	(3.06)		8.14	6.60	-	10% or higher

¹ Core EPS is calculated as an indicator showing recurring profitability by dividing core profit (determined by subtracting "other income," "other expenses" and the related "income tax expense" from "profit") by the average number of shares during the period.

² Dividend payout ratio is shown based on core EPS.

<Quarterly>

Unit: Billions of yen

	FY 2023 results				FY 2024 results					
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Change amount	Rate of change
Revenue	93.5	105.7	106.8	136.2	105.6	127.4	129.8	132.8	(3.4)	(3)%
Cost of sales	(18.9)	(28.1)	(29.9)	(34.2)	(25.6)	(33.9)	(34.5)	(38.6)	(4.4)	13%
Gross profit	74.6	77.6	76.9	101.9	80.0	93.5	95.3	94.2	(7.8)	(8)%
Gross profit to revenue ratio	79.7%	73.4%	72.0%	74.9%	75.8%	73.4%	73.4%	70.9%	-	-
Selling, general and administrative expenses	(41.8)	(40.6)	(36.9)	(43.8)	(40.2)	(43.1)	(40.4)	(43.9)	(0.2)	0%
Research and development expenses	(16.6)	(17.0)	(17.5)	(20.9)	(23.3)	(25.9)	(25.0)	(29.3)	(8.3)	40%
★ R&D expense ratio	17.8%	16.1%	16.4%	15.4%	22.1%	20.4%	19.3%	22.0%	-	-
Share of profit (loss) of investments accounted for using equity method	0.8	0.6	0.9	(1.3)	0.9	2.2	0.4	0.0	1.3	(100)%
Core operating profit	17.0	20.5	23.4	35.9	17.4	26.7	30.3	21.0	(14.9)	(42)%
★ Core operating profit ratio	18.2%	19.4%	21.9%	26.4%	16.5%	21.0%	23.3%	15.8%	-	-
Other income	0.2	0.3	16.1	0.2	2.6	1.8	8.9	(0.2)	(0.4)	(177)%
Other expenses	(2.6)	(11.6)	(2.5)	(4.4)	(2.8)	(1.9)	(12.2)	(2.4)	2.0	(45)%
Finance income (costs)	1.0	1.3	1.3	1.2	0.8	1.8	(1.9)	(6.5)	(7.7)	(658)%
Profit before tax	15.6	10.5	38.3	32.9	18.1	28.4	25.1	11.9	(21.0)	(64)%
Income tax expense	(2.8)	(1.6)	(6.4)	(5.3)	(3.5)	(5.3)	(6.9)	(7.9)	(2.6)	50%
Profit	12.8	8.9	31.9	27.6	14.6	23.1	18.1	4.0	(23.7)	(86)%
Profit to revenue ratio	13.6%	8.4%	29.9%	20.3%	13.9%	18.2%	14.0%	3.0%	-	-

2. Revenue by regional control function

Unit: Billions of yen

	FY 2023 results				FY 2024 results				FY 2025 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Jan - Dec
Japan	34.0	70.9	107.0	147.0	31.6	65.3	98.0	134.7	(12.3)	121.8
North America	25.7	60.3	92.9	137.8	32.3	79.9	120.1	174.4	36.6	191.0
EMEA	15.4	30.8	45.7	73.3	16.7	36.9	65.7	84.9	11.6	73.7
APAC	7.4	16.0	26.0	35.7	9.4	19.8	35.0	41.6	5.9	-
Others	11.0	21.2	34.5	48.4	15.6	31.1	43.9	59.9	11.5	91.5
Total consolidated revenue	93.5	199.2	306.1	442.2	105.6	233.0	362.8	495.6	53.3	478.0

* Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin (OKK) matrix global management structure, which combines a regional organization, a functional organization, and a product organization (product franchises).

* EMEA consists of Europe, the Middle East, Africa, etc.

* Revenue of APAC includes revenues received for supply of products to local partners of that region in conjunction with the business restructuring. In addition, APAC is included in Others from FY 2025.

* Others consists of revenue from technology out-licensing, hematopoietic stem cell gene therapy (revenue from Orchard Therapeutics), original equipment manufacturing, etc. The revenue from APAC is included in Others from FY 2025.

3. Revenue by location of customer

Unit: Billions of yen

	FY 2023 results					FY 2024 results				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Percentage of consolidated revenue	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Percentage of consolidated revenue
Japan	35.0	73.7	111.1	153.5	35%	34.3	68.6	100.9	141.2	28%
International	58.5	125.6	194.9	288.8	65%	71.3	164.4	261.9	354.4	72%
Americas	34.2	76.9	121.5	177.3	40%	41.9	102.3	156.0	220.4	44%
Of which, the U.S.	32.8	74.4	117.7	172.2	39%	40.7	99.6	151.8	214.9	43%
Europe	14.4	28.5	40.9	65.7	15%	16.7	35.2	63.7	80.2	16%
Asia	9.7	19.8	31.9	44.8	10%	12.3	26.3	41.3	52.5	11%
Others	0.2	0.4	0.7	1.0	0%	0.3	0.6	0.9	1.3	0%
Total consolidated revenue	93.5	199.2	306.1	442.2	100%	105.6	233.0	362.8	495.6	100%

* Revenue by location of customer is classified by region or country based on location of customer.

4. Capital expenditures and intangible assets investment, depreciation and amortization

Unit: Billions of yen

	FY 2023 results				FY 2024 results				FY 2025 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec	Jan - Dec
Capital expenditures (property, plant and equipment) ¹	3.7	7.0	10.5	16.5	4.9	12.3	19.0	29.5	34.5	34.5
Intangible assets investment	2.3	4.7	13.6	15.6	17.7	21.9	25.5	79.3	48.5	48.5
Total	6.0	11.7	24.1	32.1	22.5	34.2	44.6	108.7	83.0	83.0
Depreciation (property, plant and equipment)	3.1	6.3	9.7	13.2	<u>3.7</u>	7.4	11.0	14.8	16.5	16.5
Amortization (intangible assets)	1.8	3.6	5.8	7.9	2.0	4.7	7.8	10.0	9.0	9.0
Total	4.8	9.9	15.5	21.1	5.6	12.1	18.8	24.8	25.5	25.5

¹ Acquisitions of right-of-use assets are not included.

² The underlined portion indicates that the amount has been changed from the amount [2.6] presented in "Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2024 First Quarter" (announced on May 7, 2024).

5. Number of employees by regional control function

	FY 2023 results				FY 2024 results				Change amount
	As of March 31	As of June 30	As of September 30	As of December 31	As of March 31	As of June 30	As of September 30	As of December 31	
Japan	4,154	4,236	4,207	4,225	4,225	4,238	4,228	4,156	(69)
North America	574	608	630	638	652	661	668	672	34
EMEA	743	714	587	553	543	548	553	547	(6)
APAC	571	578	568	558	566	561	553	103	(455)
Others	-	-	-	-	168	173	185	191	191
Total	6,042	6,136	5,991	5,974	6,154	6,181	6,186	5,669	(305)

* Others consists of number of employees of Orchard Therapeutics.

II. Consolidated Statement of Cash Flows

Unit: Billions of yen

	FY 2023 results				FY 2024 results				Change amount
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	
Cash flows from operating activities	29.4	60.3	84.3	115.6	19.2	46.9	69.6	67.9	(47.7)
Cash flows from investing activities	(9.1)	(14.0)	(12.5)	(20.4)	(50.3)	(80.5)	(95.8)	(142.4)	(122.0)
Cash flows from financing activities	(15.2)	(16.1)	(31.4)	(32.5)	(41.3)	(63.2)	(83.7)	(84.7)	(52.2)
Effect of exchange rate changes on cash and cash equivalents	0.5	2.6	2.7	1.3	2.5	4.9	3.1	0.8	(0.5)
Net increase (decrease) in cash and cash equivalents	5.7	32.9	43.1	63.9	(70.0)	(91.9)	(106.8)	(158.4)	(222.3)
Cash and cash equivalents at beginning of period	339.2	339.2	339.2	339.2	403.1	403.1	403.1	403.1	63.9
Cash and cash equivalents at end of period	344.8	372.1	382.3	403.1	333.1	311.1	296.3	244.7	(158.4)

III. Revenue from Main Products

<Accumulative>

Unit: Billions of yen

Product name		FY 2023 results				FY 2024 results							FY 2025 forecasts	
		Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Jan - Dec latest forecasts	% of forecasts	Jan - Dec	Rate of change
Japan	Crysvita	2.3	4.8	7.4	10.5	2.5	5.4	8.2	11.7	1.2	12.9	91%	13.1	11%
	Poteligeo	0.4	0.9	1.4	1.9	0.4	1.0	1.4	1.8	(0.1)	1.9	95%	1.9	3%
	Nesp	0.8	1.5	2.3	3.2	0.7	1.4	2.0	2.6	(0.5)	2.8	96%	2.0	(26)%
	Darbepoetin Alfa Injection Syringe [KKF]	3.5	6.9	10.3	14.0	2.8	5.6	8.5	11.6	(2.4)	11.7	99%	9.6	(17)%
	Duvroq	1.8	4.2	6.9	9.9	2.5	5.7	8.9	12.7	2.8	12.2	104%	15.5	22%
	PHOZEVEL	-	-	-	-	0.6	1.7	2.9	4.7	4.7	3.3	141%	8.9	91%
	Regpara	0.4	0.8	1.2	1.7	0.3	0.5	0.6	0.5	(1.2)	0.9	56%		
	Orkedia	2.2	5.0	7.6	10.6	2.2	4.9	7.5	10.4	(0.2)	11.7	89%	10.7	3%
	Rocaltrol	0.7	1.4	2.1	2.9	0.6	1.2	1.9	2.5	(0.4)	2.8	89%	2.3	(10)%
	Onglyza	1.1	2.2	3.2	4.3	0.8	1.7	2.6	3.4	(0.9)	3.0	112%	2.0	(39)%
	Coniel	0.4	0.7	1.1	1.5	0.3	0.6	0.9	1.1	(0.4)	1.2	90%	1.0	(8)%
	G-Lasta	7.0	15.0	23.2	31.9	5.8	10.5	15.3	20.5	(11.4)	20.5	100%	17.0	(17)%
	Fentos	0.7	1.6	2.5	3.5	0.7	1.5	2.3	3.2	(0.3)	3.0	107%	2.9	(10)%
	Rituximab BS [KHK]	2.2	4.4	6.7	9.0	1.9	3.8	5.7	7.8	(1.2)	7.9	99%	6.0	(23)%
	Romiplate	2.7	5.7	8.7	12.0	3.0	6.5	9.9	13.9	2.0	13.2	106%	14.6	5%
	Allelock	1.9	3.1	4.1	5.5	1.7	2.7	3.5	4.1	(1.3)	3.6	116%	3.2	(23)%
	Patanol	1.4	1.5	1.7	2.0	0.8	1.0	1.1	1.3	(0.7)	1.3	97%	0.8	(38)%
	Dovobet	1.8	3.9	5.7	7.9	1.8	3.9	5.8	7.9	(0.0)	7.1	111%	-	-
	Lumicef	0.6	1.3	2.1	2.8	0.6	1.3	2.0	2.7	(0.1)	2.6	104%	2.5	(7)%
	Nourias	1.7	3.7	5.5	7.6	1.5	3.4	5.1	6.9	(0.6)	7.1	98%	6.5	(6)%
HARUROPI	0.9	2.1	3.2	4.5	1.0	2.2	3.3	4.6	0.1	5.2	89%	4.8	5%	
Depakene	0.6	1.4	2.1	2.8	0.6	1.3	1.9	2.7	(0.1)	2.4	111%	2.4	(9)%	
International	Crysvita	27.1	61.9	95.7	142.0	35.4	85.5	126.7	184.8	42.9	187.8	98%	197.1	7%
	Poteligeo	5.8	12.5	19.9	28.4	8.2	18.1	27.7	38.1	9.7	34.8	109%	43.6	14%
	Libmeldy/Lenmeldy	-	-	-	-	1.1	1.4	2.2	3.3	3.3	4.9	67%	6.9	109%
	Nourianz	1.7	3.5	5.5	8.2	1.6	3.5	6.2	8.8	0.5	9.1	96%	8.2	(7)%
	Nesp	2.2	4.4	7.0	9.1	2.9	5.7	8.8	9.7	0.6	10.7	91%		
	Regpara	0.9	1.9	3.1	4.0	1.2	2.4	3.0	3.2	(0.8)	3.9	83%		
	Neulasta/Peglasta	1.3	2.8	4.5	5.7	1.1	2.4	3.0	3.4	(2.2)	4.8	72%		
	Gran	1.4	3.2	5.2	6.9	1.8	3.7	5.4	5.4	(1.5)	7.2	76%		
	Technology out-licensing	9.2	18.4	30.1	41.9	12.1	24.3	34.9	48.8	6.9	49.0	99%	52.3	7%
Of which, Benralizumab royalty	5.7	11.6	19.1	27.4	6.4	14.4	21.6	31.4	4.0					

* Revenue from products is classified into Japan or international (other than Japan) based on consolidated revenue of regional control functions.

* Revenue listed as "Technology out-licensing" represents the upfront income, milestone revenue and running royalty income that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

* In November 2024, a voluntary recall of Regpara was announced and sales were suspended.

* Due to the termination of the distribution and co-promotion agreement with LEO Pharma K.K. for Dovobet, sales by the Company ended on December 31, 2024.

* For Regpara, Nesp, Neulasta/Peglasta and Gran, revenue generated from product supply to partners are not included following the APAC restructuring in October 2024.

* Benralizumab royalty only refers to the royalty on sales of Fasenera by AstraZeneca (including the Company's own estimates).

III. Revenue from Main Products

<Quarterly>

Unit: Billions of yen

Product name		FY 2023 results				FY 2024 results				Change amount
		Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	
Japan	Crysvita	2.3	2.5	2.6	3.1	2.5	2.9	2.8	3.6	0.5
	Poteligeo	0.4	0.5	0.5	0.5	0.4	0.5	0.4	0.5	(0.0)
	Nesp	0.8	0.8	0.8	0.8	0.7	0.7	0.6	0.7	(0.2)
	Darbepoetin Alfa Injection Syringe [KKF]	3.5	3.4	3.5	3.7	2.8	2.8	2.9	3.1	(0.5)
	Duvroq	1.8	2.4	2.6	3.1	2.5	3.2	3.3	3.8	0.7
	PHOZEVEL	-	-	-	-	0.6	1.1	1.2	1.8	1.8
	Regpara	0.4	0.5	0.4	0.4	0.3	0.2	0.2	(0.1)	(0.6)
	Orkedia	2.2	2.7	2.6	3.0	2.2	2.7	2.5	3.0	(0.0)
	Rocaltrol	0.7	0.7	0.7	0.8	0.6	0.6	0.6	0.7	(0.1)
	Onglyza	1.1	1.1	1.0	1.1	0.8	0.9	0.8	0.8	(0.3)
	Coniel	0.4	0.4	0.4	0.4	0.3	0.3	0.2	0.2	(0.2)
	G-Lasta	7.0	7.9	8.2	8.7	5.8	4.7	4.8	5.2	(3.5)
	Fentos	0.7	0.9	0.9	1.0	0.7	0.8	0.8	0.9	(0.1)
	Rituximab BS [KHK]	2.2	2.3	2.2	2.4	1.9	1.9	1.9	2.1	(0.2)
	Romiplate	2.7	3.0	3.0	3.3	3.0	3.4	3.5	4.0	0.7
	Allelock	1.9	1.2	1.0	1.3	1.7	1.0	0.8	0.7	(0.7)
	Patanol	1.4	0.2	0.2	0.3	0.8	0.2	0.1	0.1	(0.2)
	Dovobet	1.8	2.1	1.8	2.2	1.8	2.1	1.8	2.1	(0.1)
	Lumicef	0.6	0.7	0.7	0.7	0.6	0.7	0.7	0.7	(0.0)
	Nourias	1.7	2.0	1.9	2.0	1.5	1.9	1.7	1.9	(0.1)
HARUROPI	0.9	1.1	1.1	1.3	1.0	1.2	1.1	1.3	0.0	
Depakene	0.6	0.7	0.7	0.7	0.6	0.7	0.7	0.7	0.0	
International	Crysvita	27.1	34.8	33.8	46.2	35.4	50.1	41.2	58.1	11.9
	Poteligeo	5.8	6.6	7.5	8.5	8.2	9.9	9.6	10.4	1.9
	Libmeldy/Lenmeldy	-	-	-	-	1.1	0.3	0.7	1.1	1.1
	Nouriaz	1.7	1.9	2.0	2.7	1.6	2.0	2.6	2.6	(0.1)
	Nesp	2.2	2.2	2.6	2.1	2.9	2.8	3.2	0.9	(1.1)
	Regpara	0.9	1.0	1.2	1.0	1.2	1.2	0.7	0.2	(0.7)
	Neulasta/Peglasta	1.3	1.5	1.7	1.2	1.1	1.3	0.6	0.4	(0.8)
	Gran	1.4	1.8	2.0	1.8	1.8	1.9	1.8	(0.0)	(1.8)
Technology out-licensing		9.2	9.2	11.8	11.7	12.1	12.2	10.7	13.8	2.1
Of which, Benralizumab royalty		5.7	5.9	7.5	8.3	6.4	8.0	7.1	9.9	1.6

* Revenue from products is classified into Japan or international (other than Japan) based on consolidated revenue of regional control functions.

* Revenue listed as "Technology out-licensing" represents the upfront income, milestone revenue and running royalty income that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

* In November 2024, a voluntary recall of Regpara was announced and sales were suspended.

* Due to the termination of the distribution and co-promotion agreement with LEO Pharma K.K. for Dovobet, sales by the Company ended on December 31, 2024.

* For Regpara, Nesp, Neulasta/Peglasta and Gran, revenue generated from product supply to partners are not included following the APAC restructuring in October 2024.

* Benralizumab royalty only refers to the royalty on sales of Fasenna by AstraZeneca (including the Company's own estimates).

III. Revenue from Main Products

Revenue of global strategic products

<Accumulative>

Unit: Billions of yen

Product name	FY 2023 results				FY 2024 results							FY 2025 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Jan - Dec latest forecasts	% of forecasts	Jan - Dec	Rate of change
Crysvita	29.4	66.7	103.1	152.4	37.8	90.9	134.9	196.6	44.1	200.7	98%	210.2	7%
Japan	2.3	4.8	7.4	10.5	2.5	5.4	8.2	11.7	1.2	12.9	91%	13.1	11%
North America	18.8	46.0	70.2	105.2	22.8	58.7	87.2	130.0	24.8	187.8	98%	197.1	7%
[Millions of USD]	143	344	512	747	155	388	575	860	113				
EMEA	8.0	15.3	24.5	35.1	11.9	25.4	37.1	51.5	16.4				
[Millions of GBP]	50	93	144	202	64	133	193	267	65				
APAC	0.3	0.6	1.1	1.6	0.6	1.3	2.3	3.3	1.7				
Others	-	-	-	-	-	-	-	-	-	-	-	-	-
Poteligeo	6.3	13.4	21.3	30.3	8.6	19.0	29.0	39.9	9.6	36.8	109%	45.4	14%
Japan	0.4	0.9	1.4	1.9	0.4	1.0	1.4	1.8	(0.1)	1.9	95%	1.9	3%
North America	4.3	9.4	15.1	21.5	6.3	14.1	21.6	29.7	8.3	25.1	119%	34.1	15%
[Millions of USD]	33	70	110	153	43	93	143	197	44	166	118%	235	19%
EMEA	1.5	3.1	4.8	6.9	1.9	3.9	6.0	8.2	1.3	9.3	89%	9.2	12%
[Millions of GBP]	9	19	28	40	10	21	31	43	3	49	88%	48	14%
APAC	-	-	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.5	32%	-	-
Others	-	-	-	-	-	-	-	-	-	-	-	0.3	-
Total of global strategic products	35.7	80.1	124.5	182.7	46.4	109.9	163.9	236.5	53.7	237.5	207%	255.6	8%

* APAC will be included in Others from FY 2025.

<Quarterly>

Unit: Billions of yen

Product name	FY 2023 results				FY 2024 results				
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Change amount
Crysvita	29.4	37.3	36.4	49.3	37.8	53.0	44.0	61.7	12.4
Japan	2.3	2.5	2.6	3.1	2.5	2.9	2.8	3.6	0.5
North America	18.8	27.2	24.1	35.0	22.8	35.9	28.6	42.8	7.8
[Millions of USD]	143	202	168	235	155	233	187	285	50
EMEA	8.0	7.3	9.2	10.7	11.9	13.5	11.7	14.4	3.7
[Millions of GBP]	50	43	50	58	64	70	59	74	16
APAC	0.3	0.3	0.5	0.5	0.6	0.7	0.9	1.0	0.4
Poteligeo	6.3	7.1	8.0	9.0	8.6	10.4	10.0	10.9	2.0
Japan	0.4	0.5	0.5	0.5	0.4	0.5	0.4	0.5	(0.0)
North America	4.3	5.1	5.7	6.4	6.3	7.8	7.5	8.1	1.7
[Millions of USD]	33	37	39	43	43	51	49	54	11
EMEA	1.5	1.6	1.8	2.1	1.9	2.0	2.0	2.3	0.2
[Millions of GBP]	9	9	10	11	10	10	10	12	0
APAC	-	-	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Total of global strategic products	35.7	44.4	44.3	58.3	46.4	63.4	54.0	72.6	14.3

* Revenue is classified based on consolidated revenue from regional control functions.

* The revenue, generated in various currencies inside each corporate region, is converted and aggregated in USD for North America and in GBP for EMEA.

R&D pipeline

small molecule
 large molecule
 antibody
 HSC-GT
 Updated since Dec. 31, 2023
 Updated since Sep. 30, 2024

As of Dec. 31, 2024

Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage			[In-House or Licensed] Remarks
			PhI	PhII	PhIII	
KK8123 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia				[In-House] Clinical study is being conducted in NA and EU as a global product
KK8398 infigratinib Oral	FGFR3 Inhibitor	Achondroplasia				[QED Therapeutics] Preparation underway for Ph III in JP
ziftomenib ※ Oral	Menin Inhibitor	Acute Myeloid Leukemia (AML) (Monotherapy)				[Kura Oncology] Clinical study is being conducted in NA and EU as a global product NPM1-mutant AML
		Acute Lymphoblastic Leukemia (ALL) (Monotherapy)				Clinical study is being conducted in NA and EU as a global product KMT2A-rearranged ALL
		Acute Myeloid Leukemia (AML) (Monotherapy)				Clinical study is being conducted in NA and EU as a global product Non-NPM1-mutant AML/Non-KMT2A-rearranged AML
		Acute Myeloid Leukemia (AML) (Combination)				Clinical study is being conducted in NA as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin Clinical study is being conducted in NA and EU as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with gilteritinib, FLAG-IDA, LDAC
KK2845	Anti-TIM-3 ADC	Acute Myeloid Leukemia (AML)				[In-House] Antibody-Drug Conjugate Clinical study is being conducted in JP as a global product
OTL-203	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-IH (Hurler Syndrome)				[In-House] Rare Pediatric Disease (RPD) and Fast Track designations (FDA) Priority Medicines (PRIME) designation (EMA) Area of clinical study: NA and EU
OTL-201	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-III A (Sanfilippo Syndrome type A)		Ph I / Ph II		[In-House] Rare Pediatric Disease (RPD) designation (FDA) Preparation underway for registrational study (equivalent to Ph III study)
KHK4083/AMG 451 rocatinlimab Injection	Anti-OX40 Antibody	Moderate to Severe Atopic Dermatitis				[In-House] POTELLIGENT Human monoclonal antibody production technology Collaboration agreement with Amgen for the development of rocatinlimab in all the countries except for Japan Clinical study is being conducted in JP, NA, EU, UK, Middle East, Asia, Oceania, and other regions as a global product
		Prurigo Nodularis				Clinical study is being conducted in JP, NA, EU, Asia, and Oceania as a global product
		Moderate to Severe Asthma				Clinical study is being conducted in JP, NA, EU, Asia, and Oceania as a global product
KHK4951 tivozanib Ophthalmic	VEGF Receptor Tyrosine Kinase Inhibitor	Diabetic Macular Edema				[In-House] Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
		Neovascular Age-Related Macular Degeneration				Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
KK2260 Injection	EGFR-TfR1 Bispecific Antibody	Advanced or Metastatic Solid Tumors				[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP, and a clinical study is prepared under way for Ph I in NA as a global product
KK2269 Injection	EpCAM-CD40 Bispecific Antibody	Advanced or Metastatic Solid Tumors				[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP and NA as a global product
KK4277 Injection	Anti-PTPRS Humanized Antibody	Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus				[SBI Biotech] POTELLIGENT Clinical study is being conducted in JP and Asia

※ For detailed information on ziftomenib's development status, please refer to Kura Oncology's website. <https://kuraoncology.com/>

Major Applications and Approvals

Code Name, Generic Name, Product Name	Indication	Application/Under Review	Countries/Regions Received Approval in 2024
KRN125(pegfilgrastim, Product name in Japan:G-LASTA)	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation	–	JP
OTL-200(atidarsagene autotemcel, Product name in Europe/US : Libmeldy/Lenmeldy)	Metachromatic Leukodystrophy	–	US
KHK4827(brodalumab, Product name in Japan and Asia: Lumicef)	Palmoplantar Pustulosis	TW	–
KHK7580(evocalcet, Product name in Japan: Orkedia)	Secondary Hyperparathyroidism	–	CN, TW
AMG531(romiplostim, Product name in Japan: Romiplate)	Aplastic Anemia	TW	–
	Severe Aplastic Anemia	–	KR

Notes:

Since we withdrew an application for partial change of approved indication of KHK4827 for systemic sclerosis in Japan, the relevant information was deleted from this table.